0000950170-23-069417.txt : 20231211
0000950170-23-069417.hdr.sgml : 20231211
20231211161709
ACCESSION NUMBER: 0000950170-23-069417
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231207
FILED AS OF DATE: 20231211
DATE AS OF CHANGE: 20231211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanchez Ramiro
CENTRAL INDEX KEY: 0001830326
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39311
FILM NUMBER: 231478342
MAIL ADDRESS:
STREET 1: C/O CEREVELL THERAPEUTICS HOLDINGS INC.
STREET 2: 131 DARTMOUTH STREET SUITE 502
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001805387
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 844-304-2048
MAIL ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
FORMER COMPANY:
FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II
DATE OF NAME CHANGE: 20200303
4
1
ownership.xml
4
X0508
4
2023-12-07
0001805387
Cerevel Therapeutics Holdings, Inc.
CERE
0001830326
Sanchez Ramiro
C/O CEREVEL THERAPEUTICS HOLDINGS, INC.
222 JACOBS STREET, SUITE 200
CAMBRIDGE
MA
02141
false
true
false
false
Chief Medical Officer
true
Common Stock
2023-12-07
4
M
false
10000
3.50
A
10000
D
Common Stock
2023-12-07
4
S
false
10000
41.37
D
0
D
Stock Option (Right to Buy)
3.50
2023-12-07
4
M
false
10000
0.00
D
2029-02-27
Common Stock
10000
548435
D
These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person.
25% of the shares subject to this option vested and became exercisable on January 14, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
/s/ Mark Bodenrader, as Attorney-in-Fact
2023-12-11